For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Sales | - | 0 | - | - |
| Cost of sales | - | 0 | - | - |
| Gross profit | - | 0 | - | - |
| Board of directors compensation | 105,750 | 105,750 | 105,750 | 105,750 |
| General and administrative | 10,165 | 17,031 | 27,707 | 16,274 |
| Total expenses | 115,915 | 122,781 | 133,457 | 122,024 |
| Loss from operations before loss on liability settlement | -115,915 | -122,781 | -133,457 | - |
| Loss on liability settlement | - | 0 | -801,193 | - |
| Net loss for the period | -115,915 | -122,781 | -934,650 | -122,024 |
| Net loss for the period per common shares - basic | 0 | 0 | -0.03 | 0 |
| Net loss for the period per common shares - diluted | 0 | 0 | -0.03 | 0 |
| Weighted average number of common shares - basic | 33,521,755 | - | 32,246,755 | 29,271,755 |
| Weighted average number of common shares - diluted | 33,521,755 | 33,521,755 | 32,246,755 | 29,271,755 |
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)
BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)